Understanding medical foods under FDA regulations

Author(s):  
Claudia A. Lewis ◽  
Michelle C. Jackson ◽  
Jordan R. Bailey
PEDIATRICS ◽  
1994 ◽  
Vol 93 (5) ◽  
pp. 860-860
Author(s):  

Inborn errors of amino acid metabolism such as phenylketonuria, maternal phenylketonuria, maple syrup urine disease, homocystinuria, methylmalonic acidemia, propionic acidemia, isovaleric acidemia and other disorders of leucine metabolism, glutaric acidemia type I and tyrosinemia types I and II, and urea cycle disorders are rare diseases that are treatable by diet. Treatment might include the restriction of one or more amino acids, the restriction of total nitrogen, or the supplementation of specific substances. Untreated, these diseases culminate in severe mental retardation or death. Once diagnosis is confirmed, treatment of amino acid and urea cycle disorders must be carefully monitored by a physician with expertise in metabolic diseases. Special medical foods, commercially available, are indispensable for the active, ongoing treatment of diagnosed amino acid and urea cycle disorders. Special medical foods would, if used as the sole dietary source, represent a hazard to affected and healthy children. US Public Law (Publ L) 100-290 defines the term medical food as ". . . a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation."1 After passage of Publ L 100-290, many states provided funding for these products through Medicaid, and most states offered assistance through Crippled Children's and Women, Infant, and Children's programs. Some states now have laws mandating private insurance coverage for special medical foods. It is the position of the American Academy of Pediatrics that special medical foods that are used in the treatment of amino acid and urea cycle disorders are medical expenses that should be reimbursed.


2018 ◽  
Vol 154 (1) ◽  
pp. S84-S85
Author(s):  
Anna L. Silverman ◽  
Nicole A. Doria ◽  
Praphopphat Adhatamsoontra ◽  
Abdulaziz Almedimigh ◽  
Najwan Alsulaimi ◽  
...  

1994 ◽  
pp. 151-179 ◽  
Author(s):  
Mary K. Schmidl ◽  
Theodore P. Labuza
Keyword(s):  

2020 ◽  
Vol 9 (4) ◽  
pp. 150-154
Author(s):  
Madelaine Feldman ◽  
Michael S Reilly
Keyword(s):  
The Us ◽  
The Eu ◽  

In the US, 28 biosimilars have been approved, with 10 in the last two years. The US is keeping pace with the EU who pioneered biosimilars approvals a decade earlier. Herein, current FDA regulations and hurdles encountered for US biosimilar approval and uptake are discussed.


BMJ ◽  
2009 ◽  
Vol 339 (sep08 1) ◽  
pp. b3652-b3652
Author(s):  
J. H. Tanne

Sign in / Sign up

Export Citation Format

Share Document